Inventiva (IVA) Shares Outstanding (Weighted Average) (2018 - 2025)
Inventiva (IVA) recorded quarterly Shares Outstanding (Weighted Average) of $2.2 million in Q4 2025, down 99.63% quarter-over-quarter from $602.2 million in Q2 2025, and up 119.91% on a YoY basis from $1.0 million in Q4 2024.
Inventiva (IVA) Shares Outstanding (Weighted Average) (2018 - 2025) Analysis & Trends
Inventiva's Shares Outstanding (Weighted Average) history runs 8 years deep, the most recent figure standing at $2.2 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Weighted Average) rose 119.91% year-over-year to $2.2 million; the TTM figure through Dec 2025 stood at $2.2 million (up 119.91% YoY), while the FY2025 annual figure was $2.2 million, up 119.91% from the prior year.
- Shares Outstanding (Weighted Average) was $2.2 million for Q4 2025 at Inventiva, down from $602.2 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $836.0 million in Q2 2024 to a low of $768.28 in Q2 2022.
- Historically, Shares Outstanding (Weighted Average) has averaged $187.2 million across 5 years, with a median of $43.0 million in 2022.
- Biggest YoY gain for Shares Outstanding (Weighted Average) was 58606886.66% in 2024; the steepest drop was 98.18% in 2024.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $46.8 million in 2021, then decreased by 8.06% to $43.0 million in 2022, then soared by 30.44% to $56.1 million in 2023, then plunged by 98.18% to $1.0 million in 2024, then surged by 119.91% to $2.2 million in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $2.2 million (Q4 2025), $602.2 million (Q2 2025), and $1.0 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 417.01 Bn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 928.40 Mn |
| 10 | Inventiva | 8.93 Mn | -259.80 Mn | - | 2.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.25 Mn |
| Jun 30, 2025 | 602.20 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Jun 30, 2024 | 836.02 Mn |
| Dec 31, 2023 | 56.07 Mn |
| Oct 11, 2023 | 6.37 Mn |
| Jun 30, 2023 | 1,426.49 |
| Dec 31, 2022 | 42.99 Mn |
| Jun 30, 2022 | 768.28 |
| Dec 31, 2021 | 46.76 Mn |
| Mar 31, 2021 | 465.61 Mn |
| Dec 31, 2020 | 46.06 Mn |
| Dec 31, 2019 | 29.72 Mn |
| Dec 31, 2018 | 25.40 Mn |